The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Combining MRD assays with functional imaging in multiple myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the value of combining measurable residual disease (MRD) assays with functional imaging in patients with multiple myeloma to analyze outcomes after therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
